Pharma D&S




Market Access

In a competitive environment such as the pharmaceutical market, the ability to develop a winning Market Access strategy can make a difference.

Pharma D&S supports the Companies in the definition and implementation of strategies intended for the product valorization and the national as well as the local market access within the shortest possible time.

Here below are listed the services proposed in this respect:


− Support to the start-up of foreign Companies in Italy

− Price and Reimbursement

− Access to regional drug formularies

− Health Technology Assessment (HTA)





The support to the start-up of foreign companies offered by Pharma D&S provides for the definition, in collaboration with the client, of an operative plan, together with the definition of the business model. The proposed support includes also the activation of the regulatory procedures necessary to the recognition of the company by the Regulatory Authorities, as well as the development of an internal Quality System in line with the Quality Guidelines of the parent company and the legislative Requirements.





Pharma D&S provides the Client with all the services necessary for the analysis and definition of price strategies according to the legislation in force: preparation of the documentation for price determination request, preparation of the value dossier and possible assistance in the negotiation with the Health Authorities.





The instruments of regional pharmaceutical policy aiming at the control of the pharmaceutical expenditure require actions at local level, taking into consideration the purchase dynamics of Regions and local formulary restrictions (PTOR).

Pharma D&S may support the companies in the various steps of inclusion and maintenance of their products into the PTOR, from the elaboration of the strategy, to the preparation of the dossier, to the negotiation with regional payers.





The submission of new products for the inclusion in the lists of reimbursable products should comply with the current guidelines, requiring the documentation, through a critical data review process, of the cost/benefit ratio of a product.

Pharma D&S provides the necessary support for the realization of HTA and budget impact analyses as well as pharmacoeconomic studies.


You are here: Home Services Market Access

INFORMATIVA Questo sito o gli strumenti terzi da questo utilizzati si avvalgono di cookie necessari al funzionamento ed utili alle finalità illustrate nella cookie policy. To find out more about the cookies we use and how to delete them, see our privacy policy.

  I accept cookies from this site.